SCIENTIFIC BOARD

Tissuegraft has decided to establish a Scientific Board, composed of independent experts of international renown, with the following objectives:

– Guide the company in the actions and decisions concerning the development of products and processes, from the standpoint of innovation, the scientific rigor and their adaptability to use in the target markets;
– Evaluate the effectiveness of the results achieved, their correspondence to the assumed criteria and standards in the prototype development and in the market entry
– Ensure a scientific and strategic vision for the strengthening and growth of the company, achieving the desired targets on the scientific and technical level in the market and, in general, for the scientific community.
Tissuegraft Scientific Board fulfills the function of guarantee in terms of methodological and scientific rigor, as well as supervising the reliability of the results achieved by the Company. The Scientific Board particularly focus on the specific activities of R&D, and work to facilitate the expansion of relationships and networking with the international scientific community and with companies from the pharmaceutical, medical and biotechnologies fields, generally engaged in regenerative medicine.

Members:

Prof. Stephen F. Badylak

Prof. Stephen F. Badylak

Department of Surgery, University of Pittsburgh, USA

(Curriculum Vitae)

Prof. Eileen Ingham

Prof. Eileen Ingham

Medical Immunology School of Biomedical Sciences, University of Leeds, UK

Dr. Helen Berry

Dr. Helen Berry

Medical Immunology School of Biomedical Sciences, University of Leeds, UK

Prof. Diego Mantovani, PhD, FBSE

Prof. Diego Mantovani, PhD, FBSE

Laboratory for Biomaterials & Bioengineering-Canada Research Chair for the Innovation in Surgery, Laval University, Quebec City, Canada

(Curriculum Vitae)